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Abstract: Purpose
Malignant optic glioma of adulthood is a rare, invasive neoplasm of the anterior visual
pathway with 66 cases reported in the literature. It presents as anaplastic astrocytoma
(WHO grade III) or glioblastoma (WHO grade IV). The present case series covers the
spectrum of disease manifestations, discusses neuroradiologic findings and reviews
the current literature.
Methods
Retrospective case series of five patients from three tertiary referral centers and
literature review.
Results
Visual loss with or without pain was the presenting symptom in all patients (two
women, three men). Two patients were initially misdiagnosed as optic neuritis, and one
patient as atypical non-arteritic anterior ischemic optic neuropathy (NAION). A
neoplastic disease was suspected in the two remaining patients. MRI features were
iso- to hypointensity on T1-weighted native images, contrast enhancement, and
hyperintensity on T2-weighted images. Biopsy was generally diagnostic, however, one
patient required two biopsies for diagnosis. The series includes an exceptional case of
intraocular tumor extension and vitreous spread. The disease was lethal within one to
two years in all patients.
Conclusions
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Malignant optic glioma is a diagnostic challenge and remains a devastating and lethal
disease. Advances in the understanding of tumor biology have yet failed to translate
into effective treatment regimens.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
UniversityHospital 
Zurich  
Ophthalmology 
 
 
Zurich, April 2015 
 
 
 
 
 
 
Submission of Manuscript 
 
 
 
 
 
Dear Editor, 
 
 
Please find enclosed our revised manuscript entitled 
 
 
Malignant optic glioma – the spectrum of disease in a case series  
 
Ghislaine L Traber, MD1A, Athina Pangalu, MD1B, Manuela Neumann, MD1C, 2, Joao Costa, MD3, Michael Weller, MD1D, 
Ruth Huna-Baron, MD4, Klara Landau, MD1A 
 
1 Department of Ophthalmology (A), Institute of Neuroradiology (B), Institute of Neuropathology (C), Department of 
Neurology (D), University Hospital Zurich, Zurich, Switzerland 
2 Department of Neuropathology, University of Tübingen, Tübingen, Germany 
3  Department of Ophthalmology, Egas Moniz Hospital, Lisbon, Portugal 
4 Goldschleger Eye Institute, Sheba Medical Center, Sackle School of Medicine Tel Aviv University, Israel 
 
which we would like to submit for publication to ‘Graefe's Archive for Clinical and Experimental 
Ophthalmology’. 
 
 
The thorough review of our manuscript was much appreciated. We have addressed the issues 
raised and suggestions made by the reviewers.  
 
 
We hope that you will find our manuscript suitable for publication in ‘Graefe's Archive for 
Clinical and Experimental Ophthalmology’. 
 
 Kind regards, 
 
Ghislaine Traber 
 
Ghislaine Traber 
MD 
 
University Hospital Zurich 
Department of Ophthalmology 
Frauenklinikstrasse 24 
CH-8091 Zurich 
Switzerland 
Tel.: +41 44 255 59 40 
Fax: +41 44 255 44 38 
email: ghislaine.traber@usz.ch 
Cover Letter
Click here to download Cover Letter: revised Graefes MOG Cover Letter.doc 
Response to referees’ comments 
 
The thorough review of our manuscript was much appreciated. We have addressed 
the issues raised and suggestions made by the reviewers.  
 
Reviewer comments: 
 
Reviewer #1: The authors report on 5 patients with malignant optic gliomas. The text 
is concise and very informative with excellent illustrations. For the sake of 
completeness the authors may wish to add some minor data to the text. 
 
COMMENT 
1. A simplified table showing the current WHO classification of CNS astrocytic 
tumors. This would give the distant reader an overview of the spectrum of the tumors 
so that the contribution of this study can be better appreciated. 
RESPONSE:  
Table 1 gives an overview on the current WHO classification of CNS astrocytic 
tumors. 
 
COMMENT 
2. Except for patient 4, the site of biopsies and how they were taken are not clear.  
RESPONSE:  
This information has been added to the case descriptions in the results section.  
 
 
Reviewer #2: Dear Author, 
 
Your article on malignant optic glioma is of high scientific interest .It supposes , death 
beeing oftently occuring quite quickly , that the disease can be sometimes 
misdiagnosed in some parts of the world.The absence of effective treatment is 
compensating this unfortunate type of situation , however at this time of our scientific 
knowledges . 
 
Your article is well written but I wish to make some comments to improve your work 
and increase its impact when it will be read by others . 
 
COMMENT 
1.The paragraph Methods should be increased in density and comprise the 
description of the geographic origin of the patients .You are speaking about three 
referral centers and reading the authors names can induce in this knowledge but it 
has to be precised in this paragraph . 
RESPONSE:  
Information about the referral centers has been added in this paragraph. (p. 4) 
 
COMMENT 
Also , the ages and sex of the patients should be mentioned here . 
RESPONSE:  
Authors' Response to Reviewers' Comments
Click here to download Authors' Response to Reviewers' Comments: referees comments and response.docx 
We have now indicated gender and age in the revised Table 2.  
 
COMMENT 
Subjective functional signs described by the patients and suspected diagnosis should 
also be writte here, even if they are repeated in the table. 
RESPONSE:  
Subjective signs were again described in the results paragraph and in Table 2. 
 
COMMENT 
Did the patients have other ophthalmological examinations than Fundus examination 
( whith which type ? Biomicroscopy or/and indirect ophthalmoscopy ? )such as 
fluorescein angiography for example ? 
RESPONSE:  
This information has been added to the methods paragraph (p. 4-5) 
 
 
COMMENT 
Moreover always in this paragraph, if all patients have had radiotherapy and 
chemotherapy , the field of irradiation for radiotherapy and  
the doses for both technics should be precised .It should be interesting to know if 
there were differences in these technics according to the 3 centers . 
RESPONSE:  
The authors felt that discussion of radiotherapy and chemotherapy belongs to the 
result section and discussion sections rather than to the methods section.  
More precise information about radiotherapy and chemotherapy was given for each 
individual case (results, p. 5-8, see also revised Table 2). This topic is also 
addressed in the discussion section. (p. 11) 
 
COMMENT 
And the same remark for biopsy .A short description of the way of orbital bone 
trepanation should be given.Was it always lateral orbitotomy ? When or why could 
pterional craniotomy be choosen ? 
RESPONSE:  
Indication for lateral orbitotomy or pterional craniotomy is now described in the 
introduction p.4. Description of the surgical approach has been published elsewhere 
(Winn HR. Youmans Neurological Surgery, 6th ed. Philadelphia: Elsevier Saunders 
2011) and is felt to be beyond the scope of this paper. 
 
COMMENT 
Also it should be mentioned why you do not produce imaging details for patients 2 
and 5 .  
RESPONSE:  
Imaging is available for all five patients. The most illustrative cases were chosen for 
publication. 
 
COMMENT 
2.The paragraph Results is well presented.If it is better introduced by the paragrah 
Methods, it will be easier to be read . 
RESPONSE 
We improved the Method section accordingly. 
 
COMMENT 
3.The paragraph on Discussion should include a table on all the literature results 
.Even if it is more simple than yours and do not precise all details of the 45+16 
patients , duration of survival , suspected diagnosis, ages, sex, therapy for instance 
could be mentioned and really give to the paper another dimension . 
RESPONSE:  
Table 3 summarizes the findings of those 16 patients published since Wabbels et al. 
Wabbels et al themselves published a table summarizing the previous 45 cases.  
 
COMMENT 
Is CT Scan of any complementary interest in this optic nerve cancer ? 
RESPONSE:  
CT imaging is not helpful in diagnosing malignant optic glioma. (added to discussion 
p. 10) 
 
COMMENT 
Also in the discussion , you should explain if the modalities of irradiation have been 
changed with the time and the center, and the same for chemotherapy dosis .Why is 
the molecule TEMOZOLOMIDE choosen ? One has to know better which small 
progresses have been done in the early diagnosis , in imaging, in choices of 
chemotherapies, in modalities of irradiation.  
RESPONSE:  
These questions have been addressed in the Discussion section – see page 11. 
 
Wishing you a rapid publication with some complements of information ! 
 
 
 
Title Page 
 
Malignant optic glioma – the spectrum of disease in a case series  
 
Authors: 
Ghislaine L Traber, MD1A, Athina Pangalu, MD1B, Manuela Neumann, MD1C, 2, Joao 
Costa, MD3, Michael Weller, MD1D, Ruth Huna-Baron, MD4, Klara Landau, MD1A 
 
Affiliations: 
1 Department of Ophthalmology (A), Institute of Neuroradiology (B), Institute of 
Neuropathology (C), Department of Neurology (D), University Hospital Zurich, Zurich, 
Switzerland 
2 Department of Neuropathology, University of Tübingen, Tübingen, Germany 
3 Department of Ophthalmology, Egas Moniz Hospital, Lisbon, Portugal 
4 Goldschleger Eye Institute, Sheba Medical Center, Sackler School of Medicine Tel 
Aviv University, Israel 
 
Corresponding author:  
Ghislaine Traber, MD, Department of Ophthalmology, University Hospital Zurich, 
Frauenklinikstrasse 24, CH-8091 Zurich, Switzerland; ghislaine.traber@usz.ch; 
phone +41 44 255 59 40, fax +41 44 255 44 38. 
 
 
Manuscript
Click here to download Manuscript: revised MOG manuscript Graefe unscanned.doc 
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
ABSTRACT 
 
Purpose 
Malignant optic glioma of adulthood is a rare, invasive neoplasm of the anterior visual 
pathway with 66 cases reported in the literature. It presents as anaplastic 
astrocytoma (WHO grade III) or glioblastoma (WHO grade IV). The present case 
series covers the spectrum of disease manifestations, discusses neuroradiologic 
findings and reviews the current literature. 
 
Methods 
Retrospective case series of five patients from three tertiary referral centers and 
literature review. 
 
Results 
Visual loss with or without pain was the presenting symptom in all patients (two 
women, three men). Two patients were initially misdiagnosed as optic neuritis, and 
one patient as atypical non-arteritic anterior ischemic optic neuropathy (NAION). A 
neoplastic disease was suspected in the two remaining patients. MRI features were 
iso- to hypointensity on T1-weighted native images, contrast enhancement, and 
hyperintensity on T2-weighted images. Biopsy was generally diagnostic, however, 
one patient required two biopsies for diagnosis. The series includes an exceptional 
case of intraocular tumor extension and vitreous spread. The disease was lethal 
within one to two years in all patients. 
 
Conclusions 
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Malignant optic glioma is a diagnostic challenge and remains a devastating and lethal 
disease. Advances in the understanding of tumor biology have yet failed to translate 
into effective treatment regimens.  
 
 
Keywords 
Malignant optic glioma, glioblastoma, anaplastic astrocytoma, MRI, intraocular tumor 
extension. 
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INTRODUCTION 
Malignant optic glioma of adulthood is a rare entity first defined and reviewed by Hoyt 
et al. in 1973 {Hoyt et al., 1973, Brain, 96, 121-32}. The tumor arises in the optic 
nerve, chiasm or tract, and may present as a multifocal neoplasm. It is a high-grade 
astrocytoma, as such either an anaplastic astrocytoma (WHO grade III) or a 
glioblastoma (WHO grade IV) {Louis et al., 2007, IARC, Lyon.}. In addition to mitotic 
activity defining high-grade astrocytomas, the presence of necrosis or vascular 
proliferation is required for grade IV diagnosis. Table 1 gives an overview of the 
current WHO classification of CNS astrocytic tumors. Patients with malignant optic 
glioma usually suffer bilateral visual loss within a few weeks and die within one to two 
years. Upon initial presentation patients are frequently misdiagnosed with optic 
neuritis, anterior ischemic optic neuropathy or primary retinal vascular occlusion. 
Intraocular signs range from a normal fundus to disc edema, disc pallor and retinal 
vascular occlusions. Intraocular growth of tumor is rare. Biopsies need to be obtained 
to confirm diagnosis. Lateral orbitotomy is performed for tumors affecting the orbital 
part of the optic nerve, whereas tumors with intracerebral extension are best 
accessed by pterional craniotomy {Winn, Youmans Neurological Surgery, 6th ed. 
Philadelphia: Elsevier Saunders 2011.}. 
The present case series covers the spectrum of disease manifestations including one 
exceptional case of intraocular tumor manifestation, and allows discussion of 
neuroradiologic findings. 
 
METHODS 
Retrospective case series of five patients from three tertiary referral centers (1997 – 
2011) and literature review. Three patients from the Zurich University Hospital, 
Switzerland, one patient from the Goldschleger Eye Institute Tel Aviv, Israel, and one 
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patient from the Egas Moniz Hospital Lisbon, Portugal are reported. All patients 
underwent biomicroscopy of the fundus and imaging of brain and orbits. In two 
patients fluorescein angiography, and in one patient more extensive work-up with an 
electroretinogram, genetic testing, and temporal artery biopsy was performed. 
Diagnosis was confirmed by biopsy in all patients. No ethical board approval was 
required from our institute when the data was collected (2012-2013).  
 
RESULTS 
Three men and two women aged 54 to 76 years (mean 66.8 years) with malignant 
optic glioma were identified. Table 2 summarizes their disease manifestation and 
disease progression. 
 
Patient 1 presented with left-sided visual loss to hand movement (HM) level for five 
weeks. On examination, the patient had a left relative afferent pupillary defect 
(RAPD), a blurred left disc margin, pain on retropulsion, and a junctional scotoma. 
Fluorescein angiography showed unspecific late leakage of the left disc. These 
findings suggested a retrobulbar and prechiasmatic lesion. MRI showed involvement 
of the left optic nerve, optic chiasm, thalamus, mesencephalon and pons with 
enhancement on T1-weighted images, and hyperintensity on FLAIR and T2 images 
(Fig. 1). There was progression to disc edema with stasis retinopathy seven weeks 
later, and to optic atrophy another three months later. The right fundus was normal. 
Histopathology was obtained from a biopsy via left pterional craniotomy and revealed 
glioblastoma. The patient received combined temozolomide chemoradiotherapy with 
irradiation of the involved field (30 x  2 Gy planned, 24 x 2 Gy given), however, died 
during therapy four and a half months after diagnosis, probably due to tumorous 
infiltration of the brainstem. 
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 Patient 2 presented with painful eye movements, scintillations, right-sided visual loss 
(20/30), right RAPD and disc edema. The clinical picture and MRI scan with right 
optic nerve swelling, enhancement on T1-weighted images and hyperintensity in T2-
weighted images were interpreted as optic neuritis. The patient was placed on 
intravenous methylprednisolone and oral taper twice with resolution of pain, but had 
progressive visual loss to hand movements (HM) within two months due to a central 
scotoma in the right eye. The initial MRI scan had revealed a 2 cm lesion with 
abnormal signal intensity and a 2 mm enhancing spot in the right medial temporal 
gyrus of unknown etiology. Four months later, follow-up MRI showed progression of 
the latter. The subsequent cerebral biopsy allowed diagnosis of a multifocal 
glioblastoma. Despite combined temozolomide chemoradiotherapy with irradiation of 
the involved field (30 x 1.8 Gy), and bevacizumab salvage therapy, the patient 
experienced progressive tumor growth with bilateral involvement of the optic nerves, 
chiasm, tracts, as well as left thalamus und right temporal lobe. After seven months, 
vision in the left eye started to deteriorate, finally resulting in bilateral optic disc 
atrophy with no light perception (NLP) of the right eye and faint light perception (LP) 
of the left eye. The patient died within 18 months of disease onset. 
 
Patient 3 reported painless right-sided visual loss over night. Initial visual acuity of 
right eye HM and left eye 20/30 further deteriorated to right eye NLP and left eye 
20/400 with temporal hemianopia within six weeks. Fundoscopy showed a 
membranous structure of the right optic disc (Fig. 2a) with progressive vitreous 
spread over a four months period (Fig. 2b-c). MRI demonstrated a homogeneously 
enhancing chiasmatic tumor (Fig. 2d) with extension to both optic tracts and optic 
nerves (right intraorbital and left intracranial portion). The tumor was hyperintense on 
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T2-weighted images, and isointense on native T1 images. Biopsy via right pterional 
craniotomy allowed the diagnosis of anaplastic astrocytoma. The tumor progressed 
despite involved-field radiotherapy (34 x 1.8 Gy). The patient became comatose and 
died from pneumonia six months after diagnosis. Autopsy finally revealed 
pleomorphic, astrocytic tumor cells, pseudopalisading necrosis and microvascular 
proliferation (Fig. 2e-f), consistent with the diagnosis of glioblastoma. 
 
Patient 4 presented with painless unilateral visual blur (right 20/50, left 20/25), 
impaired color vision and RAPD in the right eye. Both fundi were normal. Automated 
perimetry revealed superior constriction on the right and an inferior arcuate defect on 
the left. MRI was read as suspected vague enhancement of the right optic nerve. 
Lumbar puncture and laboratory work-up for inflammatory or hematological diseases 
were normal. Intravenous methylprednisolone for five days and oral taper was 
initiated without effect. Vision deteriorated to NLP in both eyes within six weeks. At 
that point an electroretinogram was obtained in order to rule out carcinoma 
associated retinopathy. Genetic testing for Leber hereditary optic neuropathy was 
negative, temporal artery biopsy ruled out arteritis, and fluorescein angiography was 
normal. A follow-up MRI three months after onset of symptoms showed bilateral optic 
nerve enhancement on T1-weighted images, and hyperintensity in T2-weighted 
images. Optic nerve biopsy via lateral orbitotomy was unrevealing. MRI two months 
later showed progressive enlargement of the prechiasmatic optic nerves and chiasm 
suggestive for malignant optic glioma. Biopsy via pterional craniotomy confirmed 
glioblastoma. Combined temozolomide chemoradiotherapy was recommended. 
However, the patient decided against temozolomide. The tumor progressed despite 
involved-field irradiation (28 x 1.8 Gy) and the patient died one year after 
presentation. 
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 Patient 5 noticed painless visual loss in the right eye for five weeks. Visual acuity was 
20/100 with impaired color vision and RAPD in the right eye, and 20/30 with normal 
color vision in the left eye. Fundoscopy revealed optic disc swelling with 
hemorrhages and exsudates in the right eye. An arteritic cause could be ruled out, 
and a diagnosis of atypical NAION was made. Four months later, the patient was 
referred with progressive deterioration to LP in the right eye and visual loss in the left 
eye to finger counting level. Fundoscopy revealed shunt vessels and a combined 
retinal artery and venous occlusion in the right eye, whereas the left fundus was 
normal. Visual fields were not tested because vision was too low. The MRI was 
suggestive for malignant optic glioma with bilateral thickening and enhancement of 
the prechiasmatic optic nerves, chiasm, and tract on T1-weighted images, T1 iso- to 
hypointensity on native images, and hyperintensity on T2-weighted images (Fig. 3a-
c). The diagnosis of glioblastoma was confirmed by right optic nerve biopsy via 
pterional craniotomy. The patient underwent involved-field radiotherapy, however, 
died within seven months of symptom onset. Precise information about radiotherapy 
dose could not be retrieved from the records. 
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DISCUSSION 
Malignant optic glioma of adulthood is a rare, invasive neoplasm of the anterior visual 
pathway with 66 cases reported. By 2004, Wabbels et al. {Wabbels et al., 2004, 
Graefes Arch Clin Exp Ophthalmol, 242, 741-8} reviewed 45 cases. Including our five 
patients, 21 additional cases have been published since (Tables 2 and 3) {Hahn et 
al., 2004, Rofo, 176, 1700-1}{Danesh-Meyer et al., 2005, Arch Ophthalmol, 123, 694-
700}{Hartel et al., 2006, W V Med J, 102, 29-31}{Dinh et al., 2007, J Clin Neurosci, 
14, 502-5}{Romano et al., 2007, Neurologia, 22, 389-90}{Abou-Zeid et al., 2008, Br J 
Neurosurg, 22, 772-3}{Chacko et al., 2010, Br J Ophthalmol, 94, 782-3, 812}{Dumas-
Stoeckel et al., 2010, J Fr Ophtalmol, 33, 564-7}{Matloob et al., 2011, J Clin 
Neurosci}{Simao et al., 2011, Surv Ophthalmol, 56, 362-70}{Lincoff et al., 2012, J 
Neuroophthalmol, 32, 82-5}{Kang et al., 2012, Neuroophthalmology, 36, 59-
63}{Ashur-Fabian et al., 2013, Anticancer Drugs, 24, 315-23}{Colpak et al., 2014, 
Surv Ophthalmol}. Mean age of onset of all 66 cases is 57 years (standard deviation 
±15; range 22 – 83), with women and men almost equally affected (30 females and 
36 males). It rarely occurs in paediatric populations, either as a primary high-grade 
glioma {Cirak et al., 2000, Acta Radiol, 41, 375-6}{Wong et al., 1987, Cancer, 60, 
1847-55}{Safneck et al., 1992, Can J Neurol Sci, 19, 498-503}{Brooks et al., 1976, 
Clin Pediatr (Phila), 15, 557-61} or as malignant transformation of low-grade gliomas 
{Wilson et al., 1976, Neurology, 26, 322-5}{Wong et al., 1987, Cancer, 60, 1847-
55}{de Keizer et al., 1989, Am J Ophthalmol, 108, 717-25}{Zoeller et al., 2010, J 
Neurosurg Pediatr, 5, 507-10}. 
Patients suffer from rapidly progressive visual acuity and visual field loss, usually 
leading to blindness. Depending on tumor localization and extension, visual field 
defects might be unspecific or show localizing patterns. 
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With onset of symptoms, all our patients experienced visual loss within one to two 
months in at least one eye. Patient 2 had a delayed involvement of the fellow eye 
after seven months. Patient 1 initially seemed to have a strictly unilateral infiltration of 
the chiasm (Fig. 1) with preserved visual function of the fellow eye. However, there 
was neuroradiologic evidence of diffuse chiasmatic infiltration and extension to both 
optic tracts within four months of disease onset, two weeks before the patient passed 
away. Interestingly, purely unilateral involvement of the anterior visual pathway has 
been reported in one patient described by Wabbels et al. {Wabbels et al., 2004, 
Graefes Arch Clin Exp Ophthalmol, 242, 741-8} with a follow-up period of 12 months 
until death.  
At an early stage, clinical findings might suggest anterior ischemic optic neuropathy 
(patient 5) or inflammatory neuropathy (patient 2 and 4) with minimal neuroradiologic 
findings and transient responsiveness to steroids. However, progressive visual acuity 
and visual field deterioration, progressive dyschromatopsia, subsequent retinal 
vasular occlusions (patient 1), ocular ischemia as well as ocular pain, headaches, 
ophthalmoplegia, proptosis and other neurological deficits depending on tumor 
localization and extension {Wabbels et al., 2004, Graefes Arch Clin Exp Ophthalmol, 
242, 741-8} point towards a possible malignant infiltrative disease, and a follow-up 
MRI should be obtained.  
Neuroradiologic findings are unspecific, usually described as contrast enhancement 
and eventual thickening of the optic nerve, chiasm or tract in T1-weighted images 
{Miller, 2004, Eye (Lond), 18, 1026-37}{Wabbels et al., 2004, Graefes Arch Clin Exp 
Ophthalmol, 242, 741-8}, with iso- to hypointensity on native T1 images {Chong, 
2006, Cancer Imaging, 6, S27-31}{Friedman and Hollander, 1998, Radiographics, 
18, 1046-8}. T2 hyperintensity of the affected anterior visual pathway is a matter of 
debate {Chong, 2006, Cancer Imaging, 6, S27-31}. It was first described by Albers et 
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al. {Albers et al., 1988, Neurology, 38, 1071-4} in one patient. Friedman et al. 
{Friedman and Hollander, 1998, Radiographics, 18, 1046-8} presented a second 
case, and suggested T2 hyperintensity as a possible distinguishing feature of 
malignant optic glioma versus sarcoidosis with its tendency to hypointensity on T2-
weighted images. However, T2 signal intensity is variable in sarcoidosis {Becker et 
al., 2010, Eur J Radiol, 74, 299-313}. Most authors did not comment on 
neuroradiologic findings of T2-weighted images in malignant optic glioma. In two 
more recent cases {Hahn et al., 2004, Rofo, 176, 1700-1}{Lincoff et al., 2012, J 
Neuroophthalmol, 32, 82-5} T2 hyperintensity was described, whereas Wabbels et al. 
{Wabbels et al., 2004, Graefes Arch Clin Exp Ophthalmol, 242, 741-8} explicitly did 
not find T2 hyperintensity of the optic nerve and chiasm. Our case series supports T2 
or FLAIR hyperintensity as a characteristic, albeit unspecific finding of malignant 
optic glioma, since it was evident in all five patients. This is consistent with 
neuroradiologic findings in the better characterized cerebral high-grade gliomas 
{Clarke and Chang, 2012, Cancer J, 18, 26-31}. With regard to imaging features, 
differential diagnosis of a suspected malignant optic glioma still includes 
demyelinating, infectious, granulomatous, vasculitic and infiltrative optic neuropathies 
{Becker et al., 2010, Eur J Radiol, 74, 299-313}. CT imaging is not helpful in 
diagnosing malignant optic glioma. 
So far, obtaining a biopsy is mandatory for diagnosis, and in case of an unspecific 
inflammatory histopathologic result, the biopsy might have to be repeated in a patient 
with a progressive, presumably neoplastic disease as in our patient 4 {Matloob et al., 
2011, J Clin Neurosci}. Interestingly, patient 3 had documented progression of a 
grade III glioma (biopsy) to a grade IV glioma (autopsy), which is unique in the 
current literature on adult malignant optic glioma. However, it might also simply 
reflect the tumor heterogeneity with sampling bias. 
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Considering the aggressively invasive behavior of malignant astrocytomas, 
intraocular tumor extension is surprisingly rare. While a mechanical barrier at the 
level of the lamina cribrosa seems plausible, a biological barrier influencing local 
tumor growth might be suspected as well. Intravitreal seeding of malignant optic 
glioma of adulthood has not been reported before and makes our case 3 unique. 
Dumas-Stoeckel et al. {Dumas-Stoeckel et al., 2010, J Fr Ophtalmol, 33, 564-7} 
presented one patient in the French literature with subretinal tumor extension and 
combined central retinal vein and artery occlusion. Neither in this latter nor in our 
patient was intraocular growth confirmed histologically, though.  
The standard of care for newly diagnosed high-grade astrocytomas consists of 
surgery or biopsy as feasible followed by radiotherapy alone (WHO grade III) or 
temozolomide chemoradiotherapy (WHO grade IV). The introduction of 
temozolomide increased the median survival of glioblastoma patients by 2-3 months 
and the likelihood of 2-year survival from 10% to 26% {Stupp et al., 2005, N Engl J 
Med, 352, 987-96}. In contrast, the standard radiotherapy regimen of 54-60 Gy 
administered in 1.8-2 Gy fractions has remained essentially unaltered over the last 
decades. Risk structures such as optic nerves, chiasm or brain stem commonly 
receive no more than 54 Gy. Recurrence or progression may be treated with re-
resection, a second course of radiotherapy, or most commonly, using systemic 
alkylating agent chemotherapy or the VEGF antibody, bevacizumab {Weller et al., 
2014, Lancet Oncol, 15, e395-403}. The course of disease has not considerably 
improved over the last century {Hoyt et al., 1973, Brain, 96, 121-32}, and malignant 
optic glioma remains lethal within one to two years {Wabbels et al., 2004, Graefes 
Arch Clin Exp Ophthalmol, 242, 741-8}. The latter also holds true for our patients.  
Advances in the understanding of tumor biology have yet failed to translate into 
effective treatment regimens {Weller et al., 2012, Cancer J, 18, 40-4}. However as 
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research evolves, it is our hope that patients affected from a disease as devastating 
as malignant optic glioma will benefit from early diagnosis and treatment in the future. 
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Legends: 
Fig. 1: Coronal T2-weighted images of patient 1 with multifocal glioblastoma show 
hyperintensity of the left optic nerve (a), left chiasm (b) and infiltration of thalamus, 
mesencephalon and pons (c). Four months later the tumor diffusely infiltrated the 
whole chiasm. 
 
Fig. 2 (patient 3): A membranous structure of the right optic disc (a) progressed in 
size (b) and resulted in vitreous spread (c) over a four months period. The left optic 
nerve was unremarkable. The axial (d) MRI scan shows impressive thickening of the 
chiasm with homogeneous contrast enhancement on T1-weighted images. Autopsy 
revealed diffuse infiltration of the optic nerve and chiasm with pleomorphic, astrocytic 
tumor cells, with pseudopalisading necrosis (e) and microvascular proliferation (f), 
the two features distinguishing glioblastoma from anaplastic astrocytoma.  
 
Fig. 3 (patient 5): The coronal MRI scans show bilateral thickening of the optic nerve 
with hyperintensity in T2-weighted images (a), iso- to hypointensity in native T1-
weighted images (b) and bilateral enhancement (c) five months after onset of 
symptoms. 
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Table 1: Current WHO classification of CNS astrocytic tumors, modified from Louis et 
al. (2007) {Louis et al., 2007, IARC, Lyon.} 
 
Table 2: Summary of patient characteristics, disease manifestation and disease 
progression 
Abbreviations: OD right eye, OS left eye, OU both eyes, VL visual loss, AA anaplastic 
astrocytoma WHO grade III, GBM glioblastoma WHO grade IV, w weeks, mt months, 
TMZ/RT  TMZ radiotherapy with concomitant and adjuvant temozolomide 
(according to Stupp et al. 2005) {Stupp et al., 2005, N Engl J Med, 352, 987-96}, RT 
radiotherapy, TMZ temozolomide, NAION non-arteritic ischemic optic neuropathy, 
CAR carcinoma associated retinopathy, CRAO central retinal artery occlusion, CRVO 
central retinal vein occlusion,  hypointense,  isointense,  hyperintense, +contrast 
 contrast-enhancing. 
 
Table 3: Summary of 16 published cases since the review of 45 cases by Wabbels et 
al. (2004) {Wabbels et al., 2004, Graefes Arch Clin Exp Ophthalmol, 242, 741-8}. A 
case of gemistocytic astrocytoma was included because it had a rather malignant 
course with survival of 12 months despite multimodality treatment (Simao et al. 
2011). 
Abbreviations: NK not known, OD right eye, OS left eye, OU both eyes, AA 
anaplastic astrocytoma WHO grade III, GBM glioblastoma WHO grade IV, w weeks, 
mt months, chemo chemotherapy (chemotherapeutic agent indicated where 
available), RT radiotherapy (total dose indicated where available), chemo/RT 
combined chemoradiotherapy, TMZ temozolomide, PION posterior ischemic optic 
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neuropathy, NAION non-arteritic anterior ischemic optic neuropathy, CRAO central 
retinal artery occlusion, CRVO central retinal vein occlusion
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Malignant optic glioma 
 
 
 
Astrocytic tumors WHO grade I WHO grade II WHO grade III WHO grade IV 
Subependymal giant cell astrocytoma     
Pilocytic astrocytoma     
Pilomyxoid astrocytoma     
Diffuse astrocytoma     
Pleomorphic xanthoastrocytoma     
Anaplastic astrocytoma     
Glioblastoma     
Giant cell glioblastoma     
Gliosarcoma     
 
Table 1: Current WHO classification of CNS astrocytic tumors, modified from Louis et al. (2007) {Louis et al., 2007, IARC, Lyon.} 
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Patient Sex/Age Pain Suspected 
Diagnosis 
Fundus Visual Fields MRI Time to 
Blindness 
WHO grade Therapy Time to 
Death 
Comments 
1 M, 65 On retro- 
pulsion 
Tumor Disc edema OS 
 stasis retinopathy 
 disc atrophy  
Normal OD 
VL OS with junctional 
scotoma OD 
T1+contrast  
T2 / FLAIR 
 
 
 
5 w (OS) 
OD unknown 
IV, GBM TMZ/RT  TMZ 
(24 x 2 Gy 
given, 30 x 2 Gy 
planned) 
4.5 mt - Multifocal GBM 
2 M, 54 Yes Optic 
neuritis 
Disc edema OD 
 disc atrophy OU 
 
Central scotoma OD T1+contrast  
T2 
 
 
 
2 mt (OD) 
7 mt (OS) 
IV, GBM TMZ/RT  TMZ 
(30 x 1.8 Gy), 
Bevacizumab at 
progression 
 
18 mt - Multifocal GBM 
3 F, 64 No Tumor Disc membrane OD 
 vitreous spread  
Initially normal OS 
VL OD with temporal 
hemianopia OS 
T1 
T1+contrast  
T2 
 
 
<1 w (OD) 
6 w (OS) 
III, AA  
IV, GBM 
RT 
(34 x 1.8 Gy) 
6 mt - Intraocular tumor growth 
- III, AA (biopsy)  IV, GBM  
  (autopsy) 
4 M, 75 No Optic 
neuritis, 
CAR 
Initially normal OU OD unspecific 
OS arcuate scotoma 
T1+contrast  
T2 
 
 
 
6 w (OU) IV, GBM RT 
(28 x 1.8 Gy), 
patient decided 
against TMZ 
12 mt - Only second biopsy diagnostic 
5 F, 76 No NAION Disc edema 
 stasis retinopathy, 
exsudates 
 CRAO & CRVO OD 
Initially normal OS 
Not documented. T1 
T1+contrast  
T2 
5 w (OD) 
4 mt (OS) 
IV, GBM RT 
(dose not 
known) 
7 mt - Retinal vessel occlusion 
 
Table 2: Summary of patient characteristics, disease manifestation and disease progression 
Abbreviations: OD right eye, OS left eye, OU both eyes, VL visual loss, AA anaplastic astrocytoma WHO grade III, GBM glioblastoma WHO grade IV, w weeks, mt months, TMZ/RT  TMZ radiotherapy 
with concomitant and adjuvant temozolomide according to Stupp et al. (2005) {Stupp et al., 2005, N Engl J Med, 352, 987-96}, RT radiotherapy, TMZ temozolomide, NAION non-arteritic anterior 
ischemic optic neuropathy, CAR carcinoma associated retinopathy, CRAO central retinal artery occlusion, CRVO central retinal vein occlusion,  hypointense,  isointense,  hyperintense, +contrast  
contrast-enhancing 
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: Font: Bold
Formatted: English (U.S.)
Formatted: English (U.S.)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16
17 
18 
19 
20 
21 
22 
23 
24 
25 
26
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
Malignant optic glioma 
 
 
Author and year  Sex/Age Eye Time to 
blindness 
Presumed diagnosis Histology AA/GBM Therapy Time to death 
Hahn et al. 2004 M/53 OS NK neurosarcoidosis GBM chemo (nimustin, teniposid) 
and RT 
NK 
Danesh-Meyer et al. 2005 F/77 OU 2 mt OD 
NK OS 
arteritic PION NK (biopsy done) chemo and RT (60 Gy) 11 mt 
 M/60 OU NK inflammatory or infiltrative 
optic neuropathy 
AA RT (52 + 15 + 12.5 Gy) 20 mt 
 F/77 OU 18mt OD 
NK OS 
NAION AA RT (50.4 Gy) 30 mt 
Hartel et al. 2006 M/59 OU <1 mt OD 
NK OS 
NK GBM -- 8 w 
Dinh et al. 2007 F/48 OU NK Optic nerve tumor GBM RT (54 Gy) 
 
14 mt 
Romano et al. 2007 F/69 OU 4 mt OU NAION AA NK 
 
NK 
Abou-Zeid et al. 2008 M/56 OU <1 mt OU metastatic brain disease 
from renal primary 
GBM RT 3 mt 
Chacko et al. 2010 M/48 OU 1 mt OD 
NK OS 
optic neuritis AA chemo and RT 11 mt 
Dumas-Stoeckel et al. 
2010 
M/73 OU <1 mt OS 
4 mt OD 
NAION AA chemo/RT ~5-6 mt 
Matloob et al. 2011 F/63 OU <1 mt OD 
~3-6 mt OS 
optic neuritis GBM chemo (TMZ) 6 mt 
Simao et al. 2011 M/62 OU 3 mt OD 
NK OS 
optic nerve tumor Diffuse astrocytoma 
(gemistocytic) 
chemo and RT 12 mt 
Lincoff et al. 2012 M/83 OS <1 mt OS 
NK OD 
large differential for 
combined CRAO/CRVO 
GBM NK NK 
Kang et al. 2012 F/60 OU 2 mt OU inflammatory optic 
neuropathy 
AA or GBM (small 
sample) 
TMZ/RT (60 Gy)  TMZ 8 mt 
Ashur-Fabian et al. 2013 M/64 OU ~6 mt OS 
NK OD 
NK GBM TMZ/RT (60 Gy)  TMZ, 
propylthiouracil, carboplatin 
54 mt 
Colpak et al. 2014 M/47 OU <1 mt OS 
NK OD 
inflammatory or infiltrative 
optic neuropathy 
GBM -- 3 mt 
 
Table 3: Summary of 16 published cases since the review of 45 cases by Wabbels et al. (2004) {Wabbels et al., 2004, Graefes Arch Clin Exp Ophthalmol, 242, 741-8}. A case of gemistocytic 
astrocytoma was included because it had a rather malignant course with survival of 12 months despite multimodality treatment (Simao et al. 2011) 
Abbreviations: NK not known, OD right eye, OS left eye, OU both eyes, AA anaplastic astrocytoma WHO grade III, GBM glioblastoma WHO grade IV, w weeks, mt months, chemo chemotherapy 
(chemotherapeutic agent indicated where available), RT radiotherapy (total dose indicated where available), chemo/RT combined chemoradiotherapy, TMZ temozolomide, PION posterior ischemi c optic 
neuropathy, NAION non-arteritic anterior ischemic optic neuropathy, CRAO central retinal artery occlusion, CRVO central ret inal vein occlusion
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ABSTRACT 
 
Purpose 
Malignant optic glioma of adulthood is a rare, invasive neoplasm of the anterior visual 
pathway with 66 cases reported in the literature. It presents as anaplastic 
astrocytoma (WHO grade III) or glioblastoma (WHO grade IV). The present case 
series covers the spectrum of disease manifestations, discusses neuroradiologic 
findings and reviews the current literature. 
 
Methods 
Retrospective case series of five patients from three tertiary referral centers and 
literature review. 
 
Results 
Visual loss with or without pain was the presenting symptom in all patients (two 
women, three men). Two patients were initially misdiagnosed as optic neuritis, and 
one patient as atypical non-arteritic anterior ischemic optic neuropathy (NAION). A 
neoplastic disease was suspected in the two remaining patients. MRI features were 
iso- to hypointensity on T1-weighted native images, contrast enhancement, and 
hyperintensity on T2-weighted images. Biopsy was generally diagnostic, however, 
one patient required two biopsies for diagnosis. The series includes an exceptional 
case of intraocular tumor extension and vitreous spread. The disease was lethal 
within one to two years in all patients. 
 
Conclusions 
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Malignant optic glioma is a diagnostic challenge and remains a devastating and lethal 
disease. Advances in the understanding of tumor biology have yet failed to translate 
into effective treatment regimens.  
 
 
Keywords 
Malignant optic glioma, glioblastoma, anaplastic astrocytoma, MRI, intraocular tumor 
extension. 
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INTRODUCTION 
Malignant optic glioma of adulthood is a rare entity first defined and reviewed by Hoyt 
et al. in 1973 [1]. The tumor arises in the optic nerve, chiasm or tract, and may 
present as a multifocal neoplasm. It is a high-grade astrocytoma, as such either an 
anaplastic astrocytoma (WHO grade III) or a glioblastoma (WHO grade IV) [2]. In 
addition to mitotic activity defining high-grade astrocytomas, the presence of necrosis 
or vascular proliferation is required for grade IV diagnosis. Table 1 gives an overview 
of the current WHO classification of CNS astrocytic tumors. Patients with malignant 
optic glioma usually suffer bilateral visual loss within a few weeks and die within one 
to two years. Upon initial presentation patients are frequently misdiagnosed with optic 
neuritis, anterior ischemic optic neuropathy or primary retinal vascular occlusion. 
Intraocular signs range from a normal fundus to disc edema, disc pallor and retinal 
vascular occlusions. Intraocular growth of tumor is rare. Biopsies need to be obtained 
to confirm diagnosis. Lateral orbitotomy is performed for tumors affecting the orbital 
part of the optic nerve, whereas tumors with intracerebral extension are best 
accessed by pterional craniotomy [3]. 
The present case series covers the spectrum of disease manifestations including one 
exceptional case of intraocular tumor manifestation, and allows discussion of 
neuroradiologic findings. 
 
METHODS 
Retrospective case series of five patients from three tertiary referral centers (1997 – 
2011) and literature review. Three patients from the Zurich University Hospital, 
Switzerland, one patient from the Goldschleger Eye Institute Tel Aviv, Israel, and one 
patient from the Egas Moniz Hospital Lisbon, Portugal are reported. All patients 
underwent biomicroscopy of the fundus and imaging of brain and orbits. In two 
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patients fluorescein angiography, and in one patient more extensive work-up with an 
electroretinogram, genetic testing, and temporal artery biopsy was performed. 
Diagnosis was confirmed by biopsy in all patients. No ethical board approval was 
required from our institute when the data was collected (2012-2013).  
 
RESULTS 
Three men and two women aged 54 to 76 years (mean 66.8 years) with malignant 
optic glioma were identified. Table 2 summarizes their disease manifestation and 
disease progression. 
 
Patient 1 presented with left-sided visual loss to hand movement (HM) level for five 
weeks. On examination, the patient had a left relative afferent pupillary defect 
(RAPD), a blurred left disc margin, pain on retropulsion, and a junctional scotoma. 
Fluorescein angiography showed unspecific late leakage of the left disc. These 
findings suggested a retrobulbar and prechiasmatic lesion. MRI showed involvement 
of the left optic nerve, optic chiasm, thalamus, mesencephalon and pons with 
enhancement on T1-weighted images, and hyperintensity on FLAIR and T2 images 
(Fig. 1). There was progression to disc edema with stasis retinopathy seven weeks 
later, and to optic atrophy another three months later. The right fundus was normal. 
Histopathology was obtained from a biopsy via left pterional craniotomy and revealed 
glioblastoma. The patient received combined temozolomide chemoradiotherapy with 
irradiation of the involved field (30 x  2 Gy planned, 24 x 2 Gy given), however, died 
during therapy four and a half months after diagnosis, probably due to tumorous 
infiltration of the brainstem. 
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Patient 2 presented with painful eye movements, scintillations, right-sided visual loss 
(20/30), right RAPD and disc edema. The clinical picture and MRI scan with right 
optic nerve swelling, enhancement on T1-weighted images and hyperintensity in T2-
weighted images were interpreted as optic neuritis. The patient was placed on 
intravenous methylprednisolone and oral taper twice with resolution of pain, but had 
progressive visual loss to hand movements (HM) within two months due to a central 
scotoma in the right eye. The initial MRI scan had revealed a 2 cm lesion with 
abnormal signal intensity and a 2 mm enhancing spot in the right medial temporal 
gyrus of unknown etiology. Four months later, follow-up MRI showed progression of 
the latter. The subsequent cerebral biopsy allowed diagnosis of a multifocal 
glioblastoma. Despite combined temozolomide chemoradiotherapy with irradiation of 
the involved field (30 x 1.8 Gy), and bevacizumab salvage therapy, the patient 
experienced progressive tumor growth with bilateral involvement of the optic nerves, 
chiasm, tracts, as well as left thalamus und right temporal lobe. After seven months, 
vision in the left eye started to deteriorate, finally resulting in bilateral optic disc 
atrophy with no light perception (NLP) of the right eye and faint light perception (LP) 
of the left eye. The patient died within 18 months of disease onset. 
 
Patient 3 reported painless right-sided visual loss over night. Initial visual acuity of 
right eye HM and left eye 20/30 further deteriorated to right eye NLP and left eye 
20/400 with temporal hemianopia within six weeks. Fundoscopy showed a 
membranous structure of the right optic disc (Fig. 2a) with progressive vitreous 
spread over a four months period (Fig. 2b-c). MRI demonstrated a homogeneously 
enhancing chiasmatic tumor (Fig. 2d) with extension to both optic tracts and optic 
nerves (right intraorbital and left intracranial portion). The tumor was hyperintense on 
T2-weighted images, and isointense on native T1 images. Biopsy via right pterional 
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craniotomy allowed the diagnosis of anaplastic astrocytoma. The tumor progressed 
despite involved-field radiotherapy (34 x 1.8 Gy). The patient became comatose and 
died from pneumonia six months after diagnosis. Autopsy finally revealed 
pleomorphic, astrocytic tumor cells, pseudopalisading necrosis and microvascular 
proliferation (Fig. 2e-f), consistent with the diagnosis of glioblastoma. 
 
Patient 4 presented with painless unilateral visual blur (right 20/50, left 20/25), 
impaired color vision and RAPD in the right eye. Both fundi were normal. Automated 
perimetry revealed superior constriction on the right and an inferior arcuate defect on 
the left. MRI was read as suspected vague enhancement of the right optic nerve. 
Lumbar puncture and laboratory work-up for inflammatory or hematological diseases 
were normal. Intravenous methylprednisolone for five days and oral taper was 
initiated without effect. Vision deteriorated to NLP in both eyes within six weeks. At 
that point an electroretinogram was obtained in order to rule out carcinoma 
associated retinopathy. Genetic testing for Leber hereditary optic neuropathy was 
negative, temporal artery biopsy ruled out arteritis, and fluorescein angiography was 
normal. A follow-up MRI three months after onset of symptoms showed bilateral optic 
nerve enhancement on T1-weighted images, and hyperintensity in T2-weighted 
images. Optic nerve biopsy via lateral orbitotomy was unrevealing. MRI two months 
later showed progressive enlargement of the prechiasmatic optic nerves and chiasm 
suggestive for malignant optic glioma. Biopsy via pterional craniotomy confirmed 
glioblastoma. Combined temozolomide chemoradiotherapy was recommended. 
However, the patient decided against temozolomide. The tumor progressed despite 
involved-field irradiation (28 x 1.8 Gy) and the patient died one year after 
presentation. 
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Patient 5 noticed painless visual loss in the right eye for five weeks. Visual acuity was 
20/100 with impaired color vision and RAPD in the right eye, and 20/30 with normal 
color vision in the left eye. Fundoscopy revealed optic disc swelling with 
hemorrhages and exsudates in the right eye. An arteritic cause could be ruled out, 
and a diagnosis of atypical NAION was made. Four months later, the patient was 
referred with progressive deterioration to LP in the right eye and visual loss in the left 
eye to finger counting level. Fundoscopy revealed shunt vessels and a combined 
retinal artery and venous occlusion in the right eye, whereas the left fundus was 
normal. Visual fields were not tested because vision was too low. The MRI was 
suggestive for malignant optic glioma with bilateral thickening and enhancement of 
the prechiasmatic optic nerves, chiasm, and tract on T1-weighted images, T1 iso- to 
hypointensity on native images, and hyperintensity on T2-weighted images (Fig. 3a-
c). The diagnosis of glioblastoma was confirmed by right optic nerve biopsy via 
pterional craniotomy. The patient underwent involved-field radiotherapy, however, 
died within seven months of symptom onset. Precise information about radiotherapy 
dose could not be retrieved from the records. 
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DISCUSSION 
Malignant optic glioma of adulthood is a rare, invasive neoplasm of the anterior visual 
pathway with 66 cases reported. By 2004, Wabbels et al. [4] reviewed 45 cases. 
Including our five patients, 21 additional cases have been published since (Tables 2 
and 3) [5-18]. Mean age of onset of all 66 cases is 57 years (standard deviation ±15; 
range 22 – 83), with women and men almost equally affected (30 females and 36 
males). It rarely occurs in paediatric populations, either as a primary high-grade 
glioma [19-22] or as malignant transformation of low-grade gliomas [20, 23-25]. 
Patients suffer from rapidly progressive visual acuity and visual field loss, usually 
leading to blindness. Depending on tumor localization and extension, visual field 
defects might be unspecific or show localizing patterns. 
With onset of symptoms, all our patients experienced visual loss within one to two 
months in at least one eye. Patient 2 had a delayed involvement of the fellow eye 
after seven months. Patient 1 initially seemed to have a strictly unilateral infiltration of 
the chiasm (Fig. 1) with preserved visual function of the fellow eye. However, there 
was neuroradiologic evidence of diffuse chiasmatic infiltration and extension to both 
optic tracts within four months of disease onset, two weeks before the patient passed 
away. Interestingly, purely unilateral involvement of the anterior visual pathway has 
been reported in one patient described by Wabbels et al. [4] with a follow-up period 
of 12 months until death.  
At an early stage, clinical findings might suggest anterior ischemic optic neuropathy 
(patient 5) or inflammatory neuropathy (patient 2 and 4) with minimal neuroradiologic 
findings and transient responsiveness to steroids. However, progressive visual acuity 
and visual field deterioration, progressive dyschromatopsia, subsequent retinal 
vasular occlusions (patient 1), ocular ischemia as well as ocular pain, headaches, 
ophthalmoplegia, proptosis and other neurological deficits depending on tumor 
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localization and extension [4] point towards a possible malignant infiltrative disease, 
and a follow-up MRI should be obtained.  
Neuroradiologic findings are unspecific, usually described as contrast enhancement 
and eventual thickening of the optic nerve, chiasm or tract in T1-weighted images [4, 
26], with iso- to hypointensity on native T1 images [27, 28]. T2 hyperintensity of the 
affected anterior visual pathway is a matter of debate [27]. It was first described by 
Albers et al. [29] in one patient. Friedman et al. [28] presented a second case, and 
suggested T2 hyperintensity as a possible distinguishing feature of malignant optic 
glioma versus sarcoidosis with its tendency to hypointensity on T2-weighted images. 
However, T2 signal intensity is variable in sarcoidosis [30]. Most authors did not 
comment on neuroradiologic findings of T2-weighted images in malignant optic 
glioma. In two more recent cases [5, 15] T2 hyperintensity was described, whereas 
Wabbels et al. [4] explicitly did not find T2 hyperintensity of the optic nerve and 
chiasm. Our case series supports T2 or FLAIR hyperintensity as a characteristic, 
albeit unspecific finding of malignant optic glioma, since it was evident in all five 
patients. This is consistent with neuroradiologic findings in the better characterized 
cerebral high-grade gliomas [31]. With regard to imaging features, differential 
diagnosis of a suspected malignant optic glioma still includes demyelinating, 
infectious, granulomatous, vasculitic and infiltrative optic neuropathies [30]. CT 
imaging is not helpful in diagnosing malignant optic glioma. 
So far, obtaining a biopsy is mandatory for diagnosis, and in case of an unspecific 
inflammatory histopathologic result, the biopsy might have to be repeated in a patient 
with a progressive, presumably neoplastic disease as in our patient 4 [13]. 
Interestingly, patient 3 had documented progression of a grade III glioma (biopsy) to 
a grade IV glioma (autopsy), which is unique in the current literature on adult 
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malignant optic glioma. However, it might also simply reflect the tumor heterogeneity 
with sampling bias. 
Considering the aggressively invasive behavior of malignant astrocytomas, 
intraocular tumor extension is surprisingly rare. While a mechanical barrier at the 
level of the lamina cribrosa seems plausible, a biological barrier influencing local 
tumor growth might be suspected as well. Intravitreal seeding of malignant optic 
glioma of adulthood has not been reported before and makes our case 3 unique. 
Dumas-Stoeckel et al. [12] presented one patient in the French literature with 
subretinal tumor extension and combined central retinal vein and artery occlusion. 
Neither in this latter nor in our patient was intraocular growth confirmed histologically, 
though.  
The standard of care for newly diagnosed high-grade astrocytomas consists of 
surgery or biopsy as feasible followed by radiotherapy alone (WHO grade III) or 
temozolomide chemoradiotherapy (WHO grade IV). The introduction of 
temozolomide increased the median survival of glioblastoma patients by 2-3 months 
and the likelihood of 2-year survival from 10% to 26% [32]. In contrast, the standard 
radiotherapy regimen of 54-60 Gy administered in 1.8-2 Gy fractions has remained 
essentially unaltered over the last decades. Risk structures such as optic nerves, 
chiasm or brain stem commonly receive no more than 54 Gy. Recurrence or 
progression may be treated with re-resection, a second course of radiotherapy, or 
most commonly, using systemic alkylating agent chemotherapy or the VEGF 
antibody, bevacizumab [33]. The course of disease has not considerably improved 
over the last century [1], and malignant optic glioma remains lethal within one to two 
years [4]. The latter also holds true for our patients.  
Advances in the understanding of tumor biology have yet failed to translate into 
effective treatment regimens [34]. However as research evolves, it is our hope that 
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patients affected from a disease as devastating as malignant optic glioma will benefit 
from early diagnosis and treatment in the future. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
All authors certify that they have NO affiliations with or involvement in any 
organization or entity with any financial interest (such as honoraria; educational 
grants; participation in speakers’ bureaus; membership, employment, consultancies, 
stock ownership, or other equity interest; and expert testimony or patent-licensing 
arrangements), or non-financial interest (such as personal or professional 
relationships, affiliations, knowledge or beliefs) in the subject matter or materials 
discussed in this manuscript. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Legends: 
Fig. 1: Coronal T2-weighted images of patient 1 with multifocal glioblastoma show 
hyperintensity of the left optic nerve (a), left chiasm (b) and infiltration of thalamus, 
mesencephalon and pons (c). Four months later the tumor diffusely infiltrated the 
whole chiasm. 
 
Fig. 2 (patient 3): A membranous structure of the right optic disc (a) progressed in 
size (b) and resulted in vitreous spread (c) over a four months period. The left optic 
nerve was unremarkable. The axial (d) MRI scan shows impressive thickening of the 
chiasm with homogeneous contrast enhancement on T1-weighted images. Autopsy 
revealed diffuse infiltration of the optic nerve and chiasm with pleomorphic, astrocytic 
tumor cells, with pseudopalisading necrosis (e) and microvascular proliferation (f), 
the two features distinguishing glioblastoma from anaplastic astrocytoma.  
 
Fig. 3 (patient 5): The coronal MRI scans show bilateral thickening of the optic nerve 
with hyperintensity in T2-weighted images (a), iso- to hypointensity in native T1-
weighted images (b) and bilateral enhancement (c) five months after onset of 
symptoms. 
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Table 1: Current WHO classification of CNS astrocytic tumors, modified from Louis et 
al. (2007) [2] 
 
Table 2: Summary of patient characteristics, disease manifestation and disease 
progression 
Abbreviations: OD right eye, OS left eye, OU both eyes, VL visual loss, AA anaplastic 
astrocytoma WHO grade III, GBM glioblastoma WHO grade IV, w weeks, mt months, 
TMZ/RT  TMZ radiotherapy with concomitant and adjuvant temozolomide 
(according to Stupp et al. 2005) [32], RT radiotherapy, TMZ temozolomide, NAION 
non-arteritic ischemic optic neuropathy, CAR carcinoma associated retinopathy, 
CRAO central retinal artery occlusion, CRVO central retinal vein occlusion,  
hypointense,  isointense,  hyperintense, +contrast  contrast-enhancing. 
 
Table 3: Summary of 16 published cases since the review of 45 cases by Wabbels et 
al. (2004) [4]. A case of gemistocytic astrocytoma was included because it had a 
rather malignant course with survival of 12 months despite multimodality treatment 
(Simao et al. 2011). 
Abbreviations: NK not known, OD right eye, OS left eye, OU both eyes, AA 
anaplastic astrocytoma WHO grade III, GBM glioblastoma WHO grade IV, w weeks, 
mt months, chemo chemotherapy (chemotherapeutic agent indicated where 
available), RT radiotherapy (total dose indicated where available), chemo/RT 
combined chemoradiotherapy, TMZ temozolomide, PION posterior ischemic optic 
neuropathy, NAION non-arteritic anterior ischemic optic neuropathy, CRAO central 
retinal artery occlusion, CRVO central retinal vein occlusion
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Malignant optic glioma 
 
 
 
Astrocytic tumors WHO grade I WHO grade II WHO grade III WHO grade IV 
Subependymal giant cell astrocytoma     
Pilocytic astrocytoma     
Pilomyxoid astrocytoma     
Diffuse astrocytoma     
Pleomorphic xanthoastrocytoma     
Anaplastic astrocytoma     
Glioblastoma     
Giant cell glioblastoma     
Gliosarcoma     
 
Table 1: Current WHO classification of CNS astrocytic tumors, modified from Louis et al. (2007) [2] 
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Patient Sex/Age Pain Suspected 
Diagnosis 
Fundus Visual Fields MRI Time to 
Blindness 
WHO grade Therapy Time to 
Death 
Comments 
1 M, 65 On retro- 
pulsion 
Tumor Disc edema OS 
 stasis retinopathy 
 disc atrophy  
Normal OD 
VL OS with junctional 
scotoma OD 
T1+contrast  
T2 / FLAIR 
 
 
 
5 w (OS) 
OD unknown 
IV, GBM TMZ/RT  TMZ 
(24 x 2 Gy 
given, 30 x 2 Gy 
planned) 
4.5 mt - Multifocal GBM 
2 M, 54 Yes Optic 
neuritis 
Disc edema OD 
 disc atrophy OU 
 
Central scotoma OD T1+contrast  
T2 
 
 
 
2 mt (OD) 
7 mt (OS) 
IV, GBM TMZ/RT  TMZ 
(30 x 1.8 Gy), 
Bevacizumab at 
progression 
 
18 mt - Multifocal GBM 
3 F, 64 No Tumor Disc membrane OD 
 vitreous spread  
Initially normal OS 
VL OD with temporal 
hemianopia OS 
T1 
T1+contrast  
T2 
 
 
<1 w (OD) 
6 w (OS) 
III, AA  
IV, GBM 
RT 
(34 x 1.8 Gy) 
6 mt - Intraocular tumor growth 
- III, AA (biopsy)  IV, GBM  
  (autopsy) 
4 M, 75 No Optic 
neuritis, 
CAR 
Initially normal OU OD unspecific 
OS arcuate scotoma 
T1+contrast  
T2 
 
 
 
6 w (OU) IV, GBM RT 
(28 x 1.8 Gy), 
patient decided 
against TMZ 
12 mt - Only second biopsy diagnostic 
5 F, 76 No NAION Disc edema 
 stasis retinopathy, 
exsudates 
 CRAO & CRVO OD 
Initially normal OS 
Not documented. T1 
T1+contrast  
T2 
5 w (OD) 
4 mt (OS) 
IV, GBM RT 
(dose not 
known) 
7 mt - Retinal vessel occlusion 
 
Table 2: Summary of patient characteristics, disease manifestation and disease progression 
Abbreviations: OD right eye, OS left eye, OU both eyes, VL visual loss, AA anaplastic astrocytoma WHO grade III, GBM glioblastoma WHO grade IV, w weeks, mt months, TMZ/RT  TMZ radiotherapy 
with concomitant and adjuvant temozolomide according to Stupp et al. (2005) [32], RT radiotherapy, TMZ temozolomide, NAION non-arteritic anterior ischemic optic neuropathy, CAR carcinoma 
associated retinopathy, CRAO central retinal artery occlusion, CRVO central retinal vein occlusion,  hypointense,  isointense,  hyperintense, +contrast  contrast-enhancing 
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Malignant optic glioma 
 
 
Author and year  Sex/Age Eye Time to 
blindness 
Presumed diagnosis Histology AA/GBM Therapy Time to 
death 
Hahn et al. 2004 M/53 OS NK neurosarcoidosis GBM chemo (nimustin, teniposid) 
and RT 
NK 
Danesh-Meyer et al. 2005 F/77 OU 2 mt OD 
NK OS 
arteritic PION NK (biopsy done) chemo and RT (60 Gy) 11 mt 
 M/60 OU NK inflammatory or infiltrative 
optic neuropathy 
AA RT (52 + 15 + 12.5 Gy) 20 mt 
 F/77 OU 18mt OD 
NK OS 
NAION AA RT (50.4 Gy) 30 mt 
Hartel et al. 2006 M/59 OU <1 mt OD 
NK OS 
NK GBM -- 8 w 
Dinh et al. 2007 F/48 OU NK Optic nerve tumor GBM RT (54 Gy) 
 
14 mt 
Romano et al. 2007 F/69 OU 4 mt OU NAION AA NK 
 
NK 
Abou-Zeid et al. 2008 M/56 OU <1 mt OU metastatic brain disease 
from renal primary 
GBM RT 3 mt 
Chacko et al. 2010 M/48 OU 1 mt OD 
NK OS 
optic neuritis AA chemo and RT 11 mt 
Dumas-Stoeckel et al. 2010 M/73 OU <1 mt OS 
4 mt OD 
NAION AA chemo/RT ~5-6 mt 
Matloob et al. 2011 F/63 OU <1 mt OD 
~3-6 mt OS 
optic neuritis GBM chemo (TMZ) 6 mt 
Simao et al. 2011 M/62 OU 3 mt OD 
NK OS 
optic nerve tumor Diffuse astrocytoma 
(gemistocytic) 
chemo and RT 12 mt 
Lincoff et al. 2012 M/83 OS <1 mt OS 
NK OD 
large differential for 
combined CRAO/CRVO 
GBM NK NK 
Kang et al. 2012 F/60 OU 2 mt OU inflammatory optic 
neuropathy 
AA or GBM (small 
sample) 
TMZ/RT (60 Gy)  TMZ 8 mt 
Ashur-Fabian et al. 2013 M/64 OU ~6 mt OS 
NK OD 
NK GBM TMZ/RT (60 Gy)  TMZ, 
propylthiouracil, carboplatin 
54 mt 
Colpak et al. 2014 M/47 OU <1 mt OS 
NK OD 
inflammatory or infiltrative 
optic neuropathy 
GBM -- 3 mt 
 
Table 3: Summary of 16 published cases since the review of 45 cases by Wabbels et al. (2004) [4]. A case of gemistocytic astrocytoma was included because it had a rather malignant course with 
survival of 12 months despite multimodality treatment (Simao et al. 2011). 
Abbreviations: NK not known, OD right eye, OS left eye, OU both eyes, AA anaplastic astrocytoma WHO grade III, GBM glioblastoma WHO grade IV, w weeks, mt months, chemo chemotherapy 
(chemotherapeutic agent indicated where available), RT radiotherapy (total dose indicated where available), chemo/RT combined chemoradiotherapy, TMZ temozolomide, PION posterior ischemic optic 
neuropathy, NAION non-arteritic anterior ischemic optic neuropathy, CRAO central retinal artery occlusion, CRVO central retinal vein occlusion
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